Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influence of escitalopram on somatosensory processing in patients with major depression.

Next Previous
Trial Profile

Influence of escitalopram on somatosensory processing in patients with major depression.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacodynamics

Most Recent Events

  • 13 Apr 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov
  • 01 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
  • 28 Jan 2009 Planned end date changed from Dec 2009 to Dec 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top